دورية أكاديمية
Reciprocal interactions among Cobll1, PACSIN2, and SH3BP1 regulate drug resistance in chronic myeloid leukemia
| العنوان: | Reciprocal interactions among Cobll1, PACSIN2, and SH3BP1 regulate drug resistance in chronic myeloid leukemia |
|---|---|
| المؤلفون: | Kibeom Park, Hee‐Seop Yoo, Chang‐Kyu Oh, Joo Rak Lee, Hee Jin Chung, Ha‐Neul Kim, Soo‐Hyun Kim, Kyung‐Mi Kee, Tong Yoon Kim, Myungshin Kim, Byung‐Gyu Kim, Jae Sun Ra, Kyungjae Myung, Hongtae Kim, Seung Hun Han, Min‐Duk Seo, Yoonsung Lee, Dong‐Wook Kim |
| المصدر: | Cancer Medicine, Vol 11, Iss 21, Pp 4005-4020 (2022) |
| بيانات النشر: | Wiley, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | blastic transformation, chronic myeloid leukemia, Cobll1, PACSIN2, SH3BP1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Abstract Cobll1 affects blast crisis (BC) progression and tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML). PACSIN2, a novel Cobll1 binding protein, activates TKI‐induced apoptosis in K562 cells, and this activation is suppressed by Cobll1 through the interaction between PACSIN2 and Cobll1. PACSIN2 also binds and inhibits SH3BP1 which activates the downstream Rac1 pathway and induces TKI resistance. PACSIN2 competitively interacts with Cobll1 or SH3BP1 with a higher affinity for Cobll1. Cobll1 preferentially binds to PACSIN2, releasing SH3BP1 to promote the SH3BP1/Rac1 pathway and suppress TKI‐mediated apoptosis and eventually leading to TKI resistance. Similar interactions among Cobll1, PACSIN2, and SH3BP1 control hematopoiesis during vertebrate embryogenesis. Clinical analysis showed that most patients with CML have Cobll1 and SH3BP1 expression at the BC phase and BC patients with Cobll1 and SH3BP1 expression showed severe progression with a higher blast percentage than those without any Cobll1, PACSIN2, or SH3BP1 expression. Our study details the molecular mechanism of the Cobll1/PACSIN2/SH3BP1 pathway in regulating drug resistance and BC progression in CML. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2045-7634 |
| العلاقة: | https://doaj.org/toc/2045-7634Test |
| DOI: | 10.1002/cam4.4727 |
| الوصول الحر: | https://doaj.org/article/b46d4d333a56496f9e49e9161fbe2a8eTest |
| رقم الانضمام: | edsdoj.b46d4d333a56496f9e49e9161fbe2a8e |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edsdoj Directory of Open Access Journals edsdoj.b46d4d333a56496f9e49e9161fbe2a8e 999 3 Academic Journal academicJournal 998.95263671875 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.b46d4d333a56496f9e49e9161fbe2a8e&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://doaj.org/article/b46d4d333a56496f9e49e9161fbe2a8e [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=20457634&ISBN=&volume=11&issue=21&date=20221101&spage=4005&pages=4005-4020&title=Cancer Medicine&atitle=Reciprocal%20interactions%20among%20Cobll1%2C%20PACSIN2%2C%20and%20SH3BP1%20regulate%20drug%20resistance%20in%20chronic%20myeloid%20leukemia&id=DOI:10.1002/cam4.4727 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Reciprocal interactions among Cobll1, PACSIN2, and SH3BP1 regulate drug resistance in chronic myeloid leukemia
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Kibeom+Park%22">Kibeom Park</searchLink><br /><searchLink fieldCode="AR" term="%22Hee‐Seop+Yoo%22">Hee‐Seop Yoo</searchLink><br /><searchLink fieldCode="AR" term="%22Chang‐Kyu+Oh%22">Chang‐Kyu Oh</searchLink><br /><searchLink fieldCode="AR" term="%22Joo+Rak+Lee%22">Joo Rak Lee</searchLink><br /><searchLink fieldCode="AR" term="%22Hee+Jin+Chung%22">Hee Jin Chung</searchLink><br /><searchLink fieldCode="AR" term="%22Ha‐Neul+Kim%22">Ha‐Neul Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Soo‐Hyun+Kim%22">Soo‐Hyun Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Kyung‐Mi+Kee%22">Kyung‐Mi Kee</searchLink><br /><searchLink fieldCode="AR" term="%22Tong+Yoon+Kim%22">Tong Yoon Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Myungshin+Kim%22">Myungshin Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Byung‐Gyu+Kim%22">Byung‐Gyu Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Jae+Sun+Ra%22">Jae Sun Ra</searchLink><br /><searchLink fieldCode="AR" term="%22Kyungjae+Myung%22">Kyungjae Myung</searchLink><br /><searchLink fieldCode="AR" term="%22Hongtae+Kim%22">Hongtae Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Seung+Hun+Han%22">Seung Hun Han</searchLink><br /><searchLink fieldCode="AR" term="%22Min‐Duk+Seo%22">Min‐Duk Seo</searchLink><br /><searchLink fieldCode="AR" term="%22Yoonsung+Lee%22">Yoonsung Lee</searchLink><br /><searchLink fieldCode="AR" term="%22Dong‐Wook+Kim%22">Dong‐Wook Kim</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Cancer Medicine, Vol 11, Iss 21, Pp 4005-4020 (2022) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Wiley, 2022. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2022 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22blastic+transformation%22">blastic transformation</searchLink><br /><searchLink fieldCode="DE" term="%22chronic+myeloid+leukemia%22">chronic myeloid leukemia</searchLink><br /><searchLink fieldCode="DE" term="%22Cobll1%22">Cobll1</searchLink><br /><searchLink fieldCode="DE" term="%22PACSIN2%22">PACSIN2</searchLink><br /><searchLink fieldCode="DE" term="%22SH3BP1%22">SH3BP1</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Abstract Cobll1 affects blast crisis (BC) progression and tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML). PACSIN2, a novel Cobll1 binding protein, activates TKI‐induced apoptosis in K562 cells, and this activation is suppressed by Cobll1 through the interaction between PACSIN2 and Cobll1. PACSIN2 also binds and inhibits SH3BP1 which activates the downstream Rac1 pathway and induces TKI resistance. PACSIN2 competitively interacts with Cobll1 or SH3BP1 with a higher affinity for Cobll1. Cobll1 preferentially binds to PACSIN2, releasing SH3BP1 to promote the SH3BP1/Rac1 pathway and suppress TKI‐mediated apoptosis and eventually leading to TKI resistance. Similar interactions among Cobll1, PACSIN2, and SH3BP1 control hematopoiesis during vertebrate embryogenesis. Clinical analysis showed that most patients with CML have Cobll1 and SH3BP1 expression at the BC phase and BC patients with Cobll1 and SH3BP1 expression showed severe progression with a higher blast percentage than those without any Cobll1, PACSIN2, or SH3BP1 expression. Our study details the molecular mechanism of the Cobll1/PACSIN2/SH3BP1 pathway in regulating drug resistance and BC progression in CML. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 2045-7634 ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://doaj.org/toc/2045-7634 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1002/cam4.4727 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/b46d4d333a56496f9e49e9161fbe2a8e" linkWindow="_blank">https://doaj.org/article/b46d4d333a56496f9e49e9161fbe2a8e</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.b46d4d333a56496f9e49e9161fbe2a8e ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1002/cam4.4727
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 16
[StartPage] => 4005
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => blastic transformation
[Type] => general
)
[1] => Array
(
[SubjectFull] => chronic myeloid leukemia
[Type] => general
)
[2] => Array
(
[SubjectFull] => Cobll1
[Type] => general
)
[3] => Array
(
[SubjectFull] => PACSIN2
[Type] => general
)
[4] => Array
(
[SubjectFull] => SH3BP1
[Type] => general
)
[5] => Array
(
[SubjectFull] => Neoplasms. Tumors. Oncology. Including cancer and carcinogens
[Type] => general
)
[6] => Array
(
[SubjectFull] => RC254-282
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Reciprocal interactions among Cobll1, PACSIN2, and SH3BP1 regulate drug resistance in chronic myeloid leukemia
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kibeom Park
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hee‐Seop Yoo
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Chang‐Kyu Oh
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Joo Rak Lee
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hee Jin Chung
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ha‐Neul Kim
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Soo‐Hyun Kim
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kyung‐Mi Kee
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tong Yoon Kim
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Myungshin Kim
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Byung‐Gyu Kim
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jae Sun Ra
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kyungjae Myung
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hongtae Kim
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Seung Hun Han
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Min‐Duk Seo
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Yoonsung Lee
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Dong‐Wook Kim
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 11
[Type] => published
[Y] => 2022
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 20457634
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 11
)
[1] => Array
(
[Type] => issue
[Value] => 21
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Cancer Medicine
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |